
06/23/2025
Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the therapeutic landscape for type 2 diabetes mellitus (T2DM) and obesity. Real-world data is essential for evaluating the broader clinical utility, comparative effectiveness, and safety of GLP-1 agonists across different patient demographics and comorbidity profiles.
Categories Uncategorized Real-World Data on GLP-1 Agonists Post author By radiustx Post date June 23, 2025 Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the therapeutic landscape for type 2 diabetes mellitus (T2DM) and obesity. These agents mimic endogenous GLP-1, which enhances...